PMC:6141714 / 137088-147583 JSONTXT

{"project":"MyTest","denotations":[{"id":"30254638-26523849-35421882","span":{"begin":305,"end":308},"obj":"26523849"},{"id":"30254638-24018793-35421883","span":{"begin":697,"end":700},"obj":"24018793"},{"id":"30254638-19191336-35421884","span":{"begin":1146,"end":1149},"obj":"19191336"},{"id":"30254638-23899693-35421885","span":{"begin":1538,"end":1541},"obj":"23899693"},{"id":"30254638-19902385-35421886","span":{"begin":1872,"end":1875},"obj":"19902385"},{"id":"30254638-23140594-35421887","span":{"begin":2004,"end":2007},"obj":"23140594"},{"id":"30254638-25005115-35421888","span":{"begin":2348,"end":2351},"obj":"25005115"},{"id":"30254638-23922802-35421889","span":{"begin":2826,"end":2829},"obj":"23922802"},{"id":"30254638-23057962-35421890","span":{"begin":2889,"end":2892},"obj":"23057962"},{"id":"30254638-28371563-35421891","span":{"begin":3434,"end":3437},"obj":"28371563"},{"id":"30254638-23710456-35421892","span":{"begin":3615,"end":3618},"obj":"23710456"},{"id":"30254638-26700612-35421893","span":{"begin":3935,"end":3938},"obj":"26700612"},{"id":"30254638-18325660-35421894","span":{"begin":5035,"end":5038},"obj":"18325660"},{"id":"30254638-26584349-35421895","span":{"begin":5138,"end":5141},"obj":"26584349"},{"id":"30254638-26987803-35421896","span":{"begin":5536,"end":5539},"obj":"26987803"},{"id":"30254638-25064057-35421897","span":{"begin":5801,"end":5804},"obj":"25064057"},{"id":"30254638-23826999-35421898","span":{"begin":5911,"end":5914},"obj":"23826999"},{"id":"30254638-27697286-35421899","span":{"begin":6224,"end":6227},"obj":"27697286"},{"id":"30254638-22568986-35421900","span":{"begin":6724,"end":6727},"obj":"22568986"},{"id":"30254638-26757144-35421901","span":{"begin":6877,"end":6880},"obj":"26757144"},{"id":"30254638-25310756-35421902","span":{"begin":7645,"end":7648},"obj":"25310756"},{"id":"30254638-23061813-35421903","span":{"begin":8021,"end":8024},"obj":"23061813"},{"id":"30254638-23684533-35421904","span":{"begin":8286,"end":8289},"obj":"23684533"},{"id":"30254638-25436769-35421905","span":{"begin":8386,"end":8389},"obj":"25436769"},{"id":"30254638-17652844-35421906","span":{"begin":8615,"end":8618},"obj":"17652844"},{"id":"30254638-20696022-35421907","span":{"begin":8771,"end":8774},"obj":"20696022"},{"id":"30254638-26646841-35421908","span":{"begin":9001,"end":9004},"obj":"26646841"},{"id":"30254638-26807122-35421909","span":{"begin":9499,"end":9502},"obj":"26807122"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Table 7 List of in vivo studies in which the therapeutic potential of the administration of hMSCs for the treatment of autoimmune neurologic disorders was evaluated.\nReferences Autoimmune disease Source of hMSC Variables Experimental model Clinical and laboratory effects Mechanism proposed\n(102) Multiple sclerosis Embryonic stem cells Bone marrow None Mice ↓Clinical score↓Disease incidence↑Motor functions Effectiveness embryonic stem cells-derived MSCs \u003e effectiveness bone marrow-derived MSCs ↓IFN-γ+CD4+ Th1 cells into the central nervous system↓IL-17+CD4+ Th17 cells into the central nervous system↓T lymphocyte proliferation↓B lymphocyte proliferation↑PD-L1 expression\n(121) Multiple sclerosis Adipose tissue Administration of MSCs from older donors Mice None\nAdministration of MSCs from younger donors ↓Clinical score↑Activity and utilization of the arena space↑Distance traveled↑Moving velocity↑Myelin levels Effectiveness MSCs from younger donors \u003e effectiveness MSCs from older donors ↓Infiltrating cells in the spinal cord↓Splenocyte proliferation↑IL-17 in the serum↑IL-12 in the serum↑IFN-γ in the serum\n(122) Multiple sclerosis Bone marrow None Mice ↓Clinical score↓Disease progression ↑Oligodendrocyte lineage cells in lesion areas↓IFN-γ+CD4+ Th1 cells↓IL-17+CD4+ Th17 cells↑IL-4+Th2 cells↓Infiltrating cells in the central nervous system↓Extent of the chronic demyelinated regions↑Oligodendrogenesis↓Astrogliosis↓Myelin-specific memory splenocytes↓IFN-γ↓TNF-α↓IL-17↓IL-2↓IL-12↑IL-4↑IL-5\n(154) Multiple sclerosis Bone marrow None Mice ↓Clinical scores↓Demyelination in the spinal cord ↓Infiltration of inflammatory cells↓IL-6 in the serum↓TNF-α in the serum↓IL-17 in the serum↓Splenic cell production and secretion of IL-6, TNF-α and IL-17↑Splenic production of IL-10↓Splenic Th17 cells↑CD19+CD5+CD1dhigh Breg cells\n(123) Multiple sclerosis Bone marrow None Mice ↓Disease progression↑Survival rates↑Motor function ↓Spleen cells proliferation\n(124) Multiple sclerosis Umbilical cord stroma None Mice ↓Histopathologic scores↓Clinical score↓Demyelination in the spinal cord↓Axonal injury in the spinal cord ↓Perivascular immune cell infiltration↓IL-17+CD4+ Th17 cells↓IFN-γ/IL-4 ratio↑CD4+CD25+FOXP3+ Treg cells↑IL-4↑IL-10↓IL-17↓TNF-α↓IL-1 in the spinal cord↓IL-6 in the spinal cord\n(126) Multiple sclerosis Bone marrow None Mice ↓Average clinical score↓Maximum clinical score↓Demyelination of the spinal cord ↓Inflammatory cell infiltration into the central nervous system↓Inflammatory mononuclear cell infiltration in the white matter of the spinal cord↓CD4+ cells in the spinal cord↓Activation of glial cells↓IFN-γ in the serum↓TNF-α in the serum↑IL-4 in the serum↑IL-10 in the serum↓MMP-2 activity in the spinal cord↓MMP-9 activity in the spinal cord\n(127) Multiple sclerosis Bone marrow None Mice None None\n(128) Multiple sclerosis Bone marrow None Mice ↓Daily mean clinical score↓Daily mean clinical score↓Maximal disease score↓Cumulative disease score ↓Proliferation of mitogen or antigen-stimulated T-cells↓IFN- γ↓IL-2\nAdipose tissue Effectiveness adipose tissue and umbilical cord-derived MSCs \u003e effectiveness bone marrow-derived MSCs ↓IL-17 (Ad-MSCs and BMSCs only)↓TNF-α (Ad-MSCs and UC-MSCs only)↑IL-6 (BMSCs only)\nUmbilical cord stroma ↓Daily mean clinical score↓Maximal disease score↓Cumulative disease score ↑IL-10 (BMSCs only)\n(129) Multiple sclerosis Placenta Intramuscular implantation of MSCs Mice ↓Disease progression None\nDirect injection of MSCs into the central nervous system ↓Clinical score\n(133) Multiple sclerosis Bone marrow None Mice ↓Disease progression↓Average clinical score↓Maximum clinical score↓Demyelination of the lumbar spinal cord↓Blood-brain barrier permeability ↓Immune cell infiltration in the lumbar spinal cord↓IFN-γ in the serum↓TNF-α in the serum↑IL-4 in the serum↑IL-10 in the serum\n(136) Multiple sclerosis Adipose tissue Administration of MSCs isolated from lean subjects Mice ↓Disease progression↓Clinical score↑Total distance traveled↑Moving duration↑Total velocity↑Myelin content in the central nervous system Effectiveness MSCs from lean subjects \u003e effectiveness MSCs from obese subjects ↓Cell infiltration into the central nervous system↓Proliferation of T cells↓Proliferation of memory CD44+ T cells\nAdministration of MSCs isolated from obese subjects ↓Myelin content in the central nervous system ↑Cell infiltration into the central nervous system↓Overall size of the lymph nodes↑Size of the spleen↑Proliferation of T cells↑Differentiation of T cells into mature CD4+ and CD8+ T cells↑IL-1 gene expression (MSCs from lean subjects)↑IL-6 gene expression (MSCs from lean subjects)↑IL-12 gene expression (MSCs from lean subjects)↑PDGF gene expression (MSCs from lean subjects)↑TNF-α gene expression (MSCs from lean subjects)↑LIF gene expression (MSCs from lean subjects)↑ICAM-1 gene expression (MSCs from lean subjects)↑G-CSF gene expression (MSCs from lean subjects)\n(137) Multiple sclerosis Bone marrow None Mice ↓Disease progression ↓T lymphocytes proliferation\n(138) Multiple sclerosis Bone marrow Administration of PSGL-1/SLeX mRNA-transfected MSCsAdministration of MSCs alone Mice ↓Clinical score↑Neurological function↑ Myelination Effectiveness PSGL-1/SLeX mRNA-transfected MSCs \u003e effectiveness MSCs alone ↑Percentage of rolling and adherent cells↓Proliferation of CD4+ T lymphocytes↓Lymphocytes infiltration into the white matter of the spinal cord\n(139) Multiple sclerosis Placenta None Mice ↓Disease progression↓Clinical score ↓Inflammatory cell infiltration↓CD4+IL17+ Th17 cells↓CD11b+Ly6G+ neutrophils↓CD11b+Ly6C+ inflammatory monocytes↓Spleen cells proliferation↓IL-17↑IL-4↑IL-10↓RORγT gene↑GATA-3 gene\n(141) Multiple sclerosis Adipose tissue None Mice ↓Astrogliosis ↑GSK3β+ neurons in the spinal cord↑IL-4\n(143) Multiple sclerosis Bone marrow None Mice ↓Clinical score↓Demyelination in the spinal cord↓Astrocytes Treatment with hBM-MSCs and minocycline \u003e treatment with hBM-MSCs or minocycline alone ↓Microglia cells↑NeuN-positive neurons in the gray matter and spinal cord↓Apoptotic cells↓IFN-γ↓TNF-α↑IL-4↑IL-10\n(144) Multiple sclerosis Umbilical cord stroma Administration of umbilical cord derived-MSCs previously treated with IFN-γAbsence of stimulation of MSCs with IFN-γ prior to administration Mice ↓Clinical scores↓Disease progression Effectiveness MSCs + IFN-γ \u003e effectiveness MSCs alone ↓Leukocyte infiltration in the spinal cord white matter↑CD4+CD25+Foxp3+CD127low/neg Treg cells in cervical lymph nodes cells and splenocytes↓PBMCs proliferation (in vitro)↑IL-10↑IL-4↑HGF↑VEGF↑TGF-β↓IFN-γ↓IL-17\n(145) Multiple sclerosis Adipose tissue None Mice ↓Clinical scores↑Survival rates ↓Peripheral MOG-specific T-cell responses↓IFN-γ↓IL-17A↓IL-6↑IL-4\n(130) Multiple sclerosis Adipose tissue None Rats ↓Disease progression↓Mean clinical scores↓Histopathologic score↓Vascular congestion↓Axonal loss of the gray and white matters of cerebral cortex ↓Immune cell infiltration↑HLA-G gene expression in lymph nodes and brains↓CD3 mRNA expression expression in the brain↓CD19 mRNA expression expression in the brain↓CD11b mRNA expression expression in the brain↓IFN-γ in the serum↓IL-17 in the serum↑IL-4 in the serum↑IL-10 in the serum\n(140) Multiple sclerosis Adipose tissue None Rats ↓Duration of paralysis↓Disease progression↓Clinical score ↓Inflammatory cell infiltration in the spinal cord↑IL-10 gene expression in the lymph node↑IDO gene expression in the lymph node↑IFN-γ gene expression in the lymph node\n(142) Multiple sclerosis Umbilical cord stroma None Rats ↓Clinical score ↓Proliferation of activated T cells↓Autoantigen-induced T-cell proliferation↓Dendritic cell differentiation and maturation↑IDO-1↓IFN-γ↑IL-10↑LIF gene↑PD-L1 gene↑COX-2 gene↑TGF- β1 gene↑TSG-6 gene↑CD200 gene↑HGF gene↑HLA-E gene↑HLA-G gene↑HO-1 gene↑BDNF gene↑CNTF gene↑GDNF gene↑NGF gene↑NTF3 gene\n(125) Multiple sclerosis Bone marrow None Humans ↓Expanded disability status scale score None\n(131) Multiple sclerosis Bone marrow None Humans ↓Expanded disability status scale score ↓CD45RO+ memory T-lymphocytes↓Myelin-stimulated T cells proliferation\n(132) Multiple sclerosis Bone marrow None Humans ↓Expanded disability status scale score None\n(134) Multiple sclerosis Bone marrow None Humans ↓Mean cumulative number of gadolinium-enhancing lesions↓Expanded disability status scale score ↑ CD19+IL-10+ Breg cells frequency↓Breg/CD19+ cells ratio↓Th1/Th17 cells ratio\n(135) Multiple sclerosis Bone marrow None Humans ↓Expanded disability status scale score↑Sensory function↑Pyramidal function↑Cerebellar function None\n(146) Autoimmune myasthenia gravis Bone marrow None Mice ↓Mean clinical score ↓Anti-acetylcholine receptor antibody levels (in the serum)↓AchR-specific lymphocyte proliferation (in the serum)↓Mononuclear cells proliferation\n(147) Autoimmune myasthenia gravis Dental pulp None Mice ↓Clinical score↑Inverted screen hang time↓Disease incidence↓Complement component three deposits in the muscle ↓Anti-muscle-specific tyrosine kinase antibody levels (in the serum)↓Neuromuscular junction IgG levels (in the serum)↓CD11b+ leukocytes in lymph nodes↓IL-6↓IL-12\n(148) Autoimmune myasthenia gravis Bone marrow None Humans ↓Quantitative myasthenia gravis score ↓Anti-acetylcholine receptor antibody levels (in the serum)\n(149) Neuromyelitis optica Bone marrow None Humans ↑Healing of pressure ulcers↑Improvement of disability↑Ability to walk None\nBoth the methodology employed and the results obtained by each article are represented in this table. MMP-2, matrix metalloproteinase-2; MMP-9, matrix metalloproteinase-9; Ad-MSCs, adipose tissue-derived mesenchymal stem cells; Uc-MSCs, umbilical cord-derived mesenchymal stem cells; BMSCs, bone marrow-derived mesenchymal stem cells; PDGF, platelet-derived growth factor; G-CSF, granulocyte-colony stimulating factor; RORγT, RAR-related orphan receptor gamma T; GSK3β, glycogen synthase kinase 3 beta; TSG-6, tumor necrosis factor-inducible gene 6 protein; HLA-E, human leukocyte antigen E; HLA-G, human leukocyte antigen G; HO-1, heme oxygenase 1; BDNF, brain-derived neurotrophic factor; CNTF, Ciliary neurotrophic factor; GDNF, glial cell-derived neurotrophic factor; NTF3, neurotrophin-3; MOG, myelin oligodendrocyte glycoprotein; AchR, acetylcholine receptor."}

{"project":"2_test","denotations":[{"id":"30254638-26523849-35421882","span":{"begin":305,"end":308},"obj":"26523849"},{"id":"30254638-24018793-35421883","span":{"begin":697,"end":700},"obj":"24018793"},{"id":"30254638-19191336-35421884","span":{"begin":1146,"end":1149},"obj":"19191336"},{"id":"30254638-23899693-35421885","span":{"begin":1538,"end":1541},"obj":"23899693"},{"id":"30254638-19902385-35421886","span":{"begin":1872,"end":1875},"obj":"19902385"},{"id":"30254638-23140594-35421887","span":{"begin":2004,"end":2007},"obj":"23140594"},{"id":"30254638-25005115-35421888","span":{"begin":2348,"end":2351},"obj":"25005115"},{"id":"30254638-23922802-35421889","span":{"begin":2826,"end":2829},"obj":"23922802"},{"id":"30254638-23057962-35421890","span":{"begin":2889,"end":2892},"obj":"23057962"},{"id":"30254638-28371563-35421891","span":{"begin":3434,"end":3437},"obj":"28371563"},{"id":"30254638-23710456-35421892","span":{"begin":3615,"end":3618},"obj":"23710456"},{"id":"30254638-26700612-35421893","span":{"begin":3935,"end":3938},"obj":"26700612"},{"id":"30254638-18325660-35421894","span":{"begin":5035,"end":5038},"obj":"18325660"},{"id":"30254638-26584349-35421895","span":{"begin":5138,"end":5141},"obj":"26584349"},{"id":"30254638-26987803-35421896","span":{"begin":5536,"end":5539},"obj":"26987803"},{"id":"30254638-25064057-35421897","span":{"begin":5801,"end":5804},"obj":"25064057"},{"id":"30254638-23826999-35421898","span":{"begin":5911,"end":5914},"obj":"23826999"},{"id":"30254638-27697286-35421899","span":{"begin":6224,"end":6227},"obj":"27697286"},{"id":"30254638-22568986-35421900","span":{"begin":6724,"end":6727},"obj":"22568986"},{"id":"30254638-26757144-35421901","span":{"begin":6877,"end":6880},"obj":"26757144"},{"id":"30254638-25310756-35421902","span":{"begin":7645,"end":7648},"obj":"25310756"},{"id":"30254638-23061813-35421903","span":{"begin":8021,"end":8024},"obj":"23061813"},{"id":"30254638-17652844-35421906","span":{"begin":8615,"end":8618},"obj":"17652844"},{"id":"30254638-20696022-35421907","span":{"begin":8771,"end":8774},"obj":"20696022"},{"id":"30254638-26646841-35421908","span":{"begin":9001,"end":9004},"obj":"26646841"},{"id":"30254638-26807122-35421909","span":{"begin":9499,"end":9502},"obj":"26807122"}],"text":"Table 7 List of in vivo studies in which the therapeutic potential of the administration of hMSCs for the treatment of autoimmune neurologic disorders was evaluated.\nReferences Autoimmune disease Source of hMSC Variables Experimental model Clinical and laboratory effects Mechanism proposed\n(102) Multiple sclerosis Embryonic stem cells Bone marrow None Mice ↓Clinical score↓Disease incidence↑Motor functions Effectiveness embryonic stem cells-derived MSCs \u003e effectiveness bone marrow-derived MSCs ↓IFN-γ+CD4+ Th1 cells into the central nervous system↓IL-17+CD4+ Th17 cells into the central nervous system↓T lymphocyte proliferation↓B lymphocyte proliferation↑PD-L1 expression\n(121) Multiple sclerosis Adipose tissue Administration of MSCs from older donors Mice None\nAdministration of MSCs from younger donors ↓Clinical score↑Activity and utilization of the arena space↑Distance traveled↑Moving velocity↑Myelin levels Effectiveness MSCs from younger donors \u003e effectiveness MSCs from older donors ↓Infiltrating cells in the spinal cord↓Splenocyte proliferation↑IL-17 in the serum↑IL-12 in the serum↑IFN-γ in the serum\n(122) Multiple sclerosis Bone marrow None Mice ↓Clinical score↓Disease progression ↑Oligodendrocyte lineage cells in lesion areas↓IFN-γ+CD4+ Th1 cells↓IL-17+CD4+ Th17 cells↑IL-4+Th2 cells↓Infiltrating cells in the central nervous system↓Extent of the chronic demyelinated regions↑Oligodendrogenesis↓Astrogliosis↓Myelin-specific memory splenocytes↓IFN-γ↓TNF-α↓IL-17↓IL-2↓IL-12↑IL-4↑IL-5\n(154) Multiple sclerosis Bone marrow None Mice ↓Clinical scores↓Demyelination in the spinal cord ↓Infiltration of inflammatory cells↓IL-6 in the serum↓TNF-α in the serum↓IL-17 in the serum↓Splenic cell production and secretion of IL-6, TNF-α and IL-17↑Splenic production of IL-10↓Splenic Th17 cells↑CD19+CD5+CD1dhigh Breg cells\n(123) Multiple sclerosis Bone marrow None Mice ↓Disease progression↑Survival rates↑Motor function ↓Spleen cells proliferation\n(124) Multiple sclerosis Umbilical cord stroma None Mice ↓Histopathologic scores↓Clinical score↓Demyelination in the spinal cord↓Axonal injury in the spinal cord ↓Perivascular immune cell infiltration↓IL-17+CD4+ Th17 cells↓IFN-γ/IL-4 ratio↑CD4+CD25+FOXP3+ Treg cells↑IL-4↑IL-10↓IL-17↓TNF-α↓IL-1 in the spinal cord↓IL-6 in the spinal cord\n(126) Multiple sclerosis Bone marrow None Mice ↓Average clinical score↓Maximum clinical score↓Demyelination of the spinal cord ↓Inflammatory cell infiltration into the central nervous system↓Inflammatory mononuclear cell infiltration in the white matter of the spinal cord↓CD4+ cells in the spinal cord↓Activation of glial cells↓IFN-γ in the serum↓TNF-α in the serum↑IL-4 in the serum↑IL-10 in the serum↓MMP-2 activity in the spinal cord↓MMP-9 activity in the spinal cord\n(127) Multiple sclerosis Bone marrow None Mice None None\n(128) Multiple sclerosis Bone marrow None Mice ↓Daily mean clinical score↓Daily mean clinical score↓Maximal disease score↓Cumulative disease score ↓Proliferation of mitogen or antigen-stimulated T-cells↓IFN- γ↓IL-2\nAdipose tissue Effectiveness adipose tissue and umbilical cord-derived MSCs \u003e effectiveness bone marrow-derived MSCs ↓IL-17 (Ad-MSCs and BMSCs only)↓TNF-α (Ad-MSCs and UC-MSCs only)↑IL-6 (BMSCs only)\nUmbilical cord stroma ↓Daily mean clinical score↓Maximal disease score↓Cumulative disease score ↑IL-10 (BMSCs only)\n(129) Multiple sclerosis Placenta Intramuscular implantation of MSCs Mice ↓Disease progression None\nDirect injection of MSCs into the central nervous system ↓Clinical score\n(133) Multiple sclerosis Bone marrow None Mice ↓Disease progression↓Average clinical score↓Maximum clinical score↓Demyelination of the lumbar spinal cord↓Blood-brain barrier permeability ↓Immune cell infiltration in the lumbar spinal cord↓IFN-γ in the serum↓TNF-α in the serum↑IL-4 in the serum↑IL-10 in the serum\n(136) Multiple sclerosis Adipose tissue Administration of MSCs isolated from lean subjects Mice ↓Disease progression↓Clinical score↑Total distance traveled↑Moving duration↑Total velocity↑Myelin content in the central nervous system Effectiveness MSCs from lean subjects \u003e effectiveness MSCs from obese subjects ↓Cell infiltration into the central nervous system↓Proliferation of T cells↓Proliferation of memory CD44+ T cells\nAdministration of MSCs isolated from obese subjects ↓Myelin content in the central nervous system ↑Cell infiltration into the central nervous system↓Overall size of the lymph nodes↑Size of the spleen↑Proliferation of T cells↑Differentiation of T cells into mature CD4+ and CD8+ T cells↑IL-1 gene expression (MSCs from lean subjects)↑IL-6 gene expression (MSCs from lean subjects)↑IL-12 gene expression (MSCs from lean subjects)↑PDGF gene expression (MSCs from lean subjects)↑TNF-α gene expression (MSCs from lean subjects)↑LIF gene expression (MSCs from lean subjects)↑ICAM-1 gene expression (MSCs from lean subjects)↑G-CSF gene expression (MSCs from lean subjects)\n(137) Multiple sclerosis Bone marrow None Mice ↓Disease progression ↓T lymphocytes proliferation\n(138) Multiple sclerosis Bone marrow Administration of PSGL-1/SLeX mRNA-transfected MSCsAdministration of MSCs alone Mice ↓Clinical score↑Neurological function↑ Myelination Effectiveness PSGL-1/SLeX mRNA-transfected MSCs \u003e effectiveness MSCs alone ↑Percentage of rolling and adherent cells↓Proliferation of CD4+ T lymphocytes↓Lymphocytes infiltration into the white matter of the spinal cord\n(139) Multiple sclerosis Placenta None Mice ↓Disease progression↓Clinical score ↓Inflammatory cell infiltration↓CD4+IL17+ Th17 cells↓CD11b+Ly6G+ neutrophils↓CD11b+Ly6C+ inflammatory monocytes↓Spleen cells proliferation↓IL-17↑IL-4↑IL-10↓RORγT gene↑GATA-3 gene\n(141) Multiple sclerosis Adipose tissue None Mice ↓Astrogliosis ↑GSK3β+ neurons in the spinal cord↑IL-4\n(143) Multiple sclerosis Bone marrow None Mice ↓Clinical score↓Demyelination in the spinal cord↓Astrocytes Treatment with hBM-MSCs and minocycline \u003e treatment with hBM-MSCs or minocycline alone ↓Microglia cells↑NeuN-positive neurons in the gray matter and spinal cord↓Apoptotic cells↓IFN-γ↓TNF-α↑IL-4↑IL-10\n(144) Multiple sclerosis Umbilical cord stroma Administration of umbilical cord derived-MSCs previously treated with IFN-γAbsence of stimulation of MSCs with IFN-γ prior to administration Mice ↓Clinical scores↓Disease progression Effectiveness MSCs + IFN-γ \u003e effectiveness MSCs alone ↓Leukocyte infiltration in the spinal cord white matter↑CD4+CD25+Foxp3+CD127low/neg Treg cells in cervical lymph nodes cells and splenocytes↓PBMCs proliferation (in vitro)↑IL-10↑IL-4↑HGF↑VEGF↑TGF-β↓IFN-γ↓IL-17\n(145) Multiple sclerosis Adipose tissue None Mice ↓Clinical scores↑Survival rates ↓Peripheral MOG-specific T-cell responses↓IFN-γ↓IL-17A↓IL-6↑IL-4\n(130) Multiple sclerosis Adipose tissue None Rats ↓Disease progression↓Mean clinical scores↓Histopathologic score↓Vascular congestion↓Axonal loss of the gray and white matters of cerebral cortex ↓Immune cell infiltration↑HLA-G gene expression in lymph nodes and brains↓CD3 mRNA expression expression in the brain↓CD19 mRNA expression expression in the brain↓CD11b mRNA expression expression in the brain↓IFN-γ in the serum↓IL-17 in the serum↑IL-4 in the serum↑IL-10 in the serum\n(140) Multiple sclerosis Adipose tissue None Rats ↓Duration of paralysis↓Disease progression↓Clinical score ↓Inflammatory cell infiltration in the spinal cord↑IL-10 gene expression in the lymph node↑IDO gene expression in the lymph node↑IFN-γ gene expression in the lymph node\n(142) Multiple sclerosis Umbilical cord stroma None Rats ↓Clinical score ↓Proliferation of activated T cells↓Autoantigen-induced T-cell proliferation↓Dendritic cell differentiation and maturation↑IDO-1↓IFN-γ↑IL-10↑LIF gene↑PD-L1 gene↑COX-2 gene↑TGF- β1 gene↑TSG-6 gene↑CD200 gene↑HGF gene↑HLA-E gene↑HLA-G gene↑HO-1 gene↑BDNF gene↑CNTF gene↑GDNF gene↑NGF gene↑NTF3 gene\n(125) Multiple sclerosis Bone marrow None Humans ↓Expanded disability status scale score None\n(131) Multiple sclerosis Bone marrow None Humans ↓Expanded disability status scale score ↓CD45RO+ memory T-lymphocytes↓Myelin-stimulated T cells proliferation\n(132) Multiple sclerosis Bone marrow None Humans ↓Expanded disability status scale score None\n(134) Multiple sclerosis Bone marrow None Humans ↓Mean cumulative number of gadolinium-enhancing lesions↓Expanded disability status scale score ↑ CD19+IL-10+ Breg cells frequency↓Breg/CD19+ cells ratio↓Th1/Th17 cells ratio\n(135) Multiple sclerosis Bone marrow None Humans ↓Expanded disability status scale score↑Sensory function↑Pyramidal function↑Cerebellar function None\n(146) Autoimmune myasthenia gravis Bone marrow None Mice ↓Mean clinical score ↓Anti-acetylcholine receptor antibody levels (in the serum)↓AchR-specific lymphocyte proliferation (in the serum)↓Mononuclear cells proliferation\n(147) Autoimmune myasthenia gravis Dental pulp None Mice ↓Clinical score↑Inverted screen hang time↓Disease incidence↓Complement component three deposits in the muscle ↓Anti-muscle-specific tyrosine kinase antibody levels (in the serum)↓Neuromuscular junction IgG levels (in the serum)↓CD11b+ leukocytes in lymph nodes↓IL-6↓IL-12\n(148) Autoimmune myasthenia gravis Bone marrow None Humans ↓Quantitative myasthenia gravis score ↓Anti-acetylcholine receptor antibody levels (in the serum)\n(149) Neuromyelitis optica Bone marrow None Humans ↑Healing of pressure ulcers↑Improvement of disability↑Ability to walk None\nBoth the methodology employed and the results obtained by each article are represented in this table. MMP-2, matrix metalloproteinase-2; MMP-9, matrix metalloproteinase-9; Ad-MSCs, adipose tissue-derived mesenchymal stem cells; Uc-MSCs, umbilical cord-derived mesenchymal stem cells; BMSCs, bone marrow-derived mesenchymal stem cells; PDGF, platelet-derived growth factor; G-CSF, granulocyte-colony stimulating factor; RORγT, RAR-related orphan receptor gamma T; GSK3β, glycogen synthase kinase 3 beta; TSG-6, tumor necrosis factor-inducible gene 6 protein; HLA-E, human leukocyte antigen E; HLA-G, human leukocyte antigen G; HO-1, heme oxygenase 1; BDNF, brain-derived neurotrophic factor; CNTF, Ciliary neurotrophic factor; GDNF, glial cell-derived neurotrophic factor; NTF3, neurotrophin-3; MOG, myelin oligodendrocyte glycoprotein; AchR, acetylcholine receptor."}